Status:
COMPLETED
Docetaxel+Carboplatin vs Epirubicin+Cyclophosphamide Followed by Docetaxel as Adjuvant Treatment in Triple-negative Breast Cancer
Lead Sponsor:
Chinese Academy of Medical Sciences
Conditions:
Breast Cancer
Eligibility:
FEMALE
18-70 years
Phase:
PHASE2
PHASE3
Brief Summary
Triple-negative breast cancer (TNBC) has a relatively bad prognosis whereas there is no standard regimen. Some data showed that platins could improve the efficacy of advance TNBC. In this trial, it is...
Eligibility Criteria
Inclusion
- Triple-negative breast cancer
- Older than 18 years old
- Have tumor resection surgery
- Sufficient organ function (marrow, heart, liver)
Exclusion
- Other malignancy
- Other serious disease( marrow, heart, liver)
Key Trial Info
Start Date :
June 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 1 2016
Estimated Enrollment :
320 Patients enrolled
Trial Details
Trial ID
NCT01150513
Start Date
June 1 2009
End Date
April 1 2016
Last Update
February 9 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Cancer Institute & Hospital Chinese Academy of Medical Sciences
Beijing, China, 100021